newsfilter
← Latest News
GlobeNewswire·

Aerovate Therapeutics Announces Full-Year 2021 Financial Results

Initiated IMPAHCT, a global Phase 2b/Phase 3 trial of AV-101 for pulmonary arterial hypertension (PAH) in December 2021 Received FDA guidance in April 2021 that our Phase 2b/Phase 3 trial could support an NDA submission based on change in six minute wa